Metoprolol CR/XL: advanced formulation of a classical beta-blocker [Metoprolol CR/XL: usovershenstvovannaia forma étalonnogo beta-blokatora.]

Metoprolol is a selective beta(1)-adrenergic antagonist extensively used in major fields of cardiology since 1975. Metoprolol has proven its efficacy in reducing cardiovascular events and mortality in patients with hypertension and coronary heart disease in large clinical trials. Recently developed controlled release/extended release (CR/XL) formulation of metoprolol succinate was designed to provide relatively constant metoprolol plasma concentrations and beta(1)-blockade while retaining the convenience of once daily administration. The avoidance of high peak plasma concentrations with metoprolol succinate is associated with lesser degree of adverse effects and may improve patients compliance. This formulation of metoprolol has demonstrated efficacy in reducing cardiovascular events and mortality in patients with heart failure. More recently evidence for antiatherogenic activity of metoprolol succinate has been also obtained.

Авторы
Редакторы
-
Журнал
Издательство
KlinMed Consulting
Номер выпуска
9
Язык
Русский
Страницы
91-100
Статус
Опубликовано
Подразделение
-
DOI
-
Номер
-
Том
43
Год
2003
Организации
  • 1 Russian University of Peoples Friendship, ul. Vavilova 61, 117292 Moscow, Russia.
Ключевые слова
beta adrenergic receptor blocking agent; drug derivative; metoprolol; metoprolol succinate; congestive heart failure; drug contraindication; heart arrhythmia; heart muscle ischemia; human; hypertension; patient compliance; review; treatment outcome; Adrenergic beta-Antagonists; Arrhythmia; Heart Failure, Congestive; Humans; Hypertension; Metoprolol; Myocardial Ischemia; Patient Compliance; Treatment Outcome
Дата создания
19.10.2018
Дата изменения
19.10.2018
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/9/